We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
story of the week
Published in Benign Hematology

Journal Scan / Research · July 08, 2021

Effect of Prescription Drug Monitoring Programs on Opioids Dispensed for Sickle Cell Disease or Cancer With Bone Metastasis

JAMA: The Journal of the American Medical Association

 

Additional Info

JAMA: The Journal of the American Medical Association
Prescription Drug Monitoring Program Mandates and Opioids Dispensed Following Emergency Department Encounters for Patients With Sickle Cell Disease or Cancer With Bone Metastasis
JAMA 2021 Jun 14;[EPub Ahead of Print], H Zhang, AS Kilaru, ZF Meisel, Y Bao

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading